About Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:DGX
- CUSIP: 74834L10
- Web: www.questdiagnostics.com
- Market Cap: $12.97 billion
- Outstanding Shares: 136,405,000
- 50 Day Moving Avg: $98.11
- 200 Day Moving Avg: $104.54
- 52 Week Range: $79.12 - $112.97
Sales & Book Value:
- Trailing P/E Ratio: 19.16
- Foreward P/E Ratio: 16.31
- P/E Growth: 2.22
- Annual Revenue: $7.59 billion
- Price / Sales: 1.71
- Book Value: $34.54 per share
- Price / Book: 2.75
- Annual Dividend: $1.80
- Dividend Yield: 1.9%
- EBITDA: $1.44 billion
- Net Margins: 8.82%
- Return on Equity: 15.53%
- Return on Assets: 7.18%
- Debt-to-Equity Ratio: 0.78%
- Current Ratio: 1.47%
- Quick Ratio: 1.55%
- Average Volume: 1.14 million shs.
- Beta: 0.65
- Short Ratio: 5.9
Frequently Asked Questions for Quest Diagnostics Incorporated (NYSE:DGX)
What is Quest Diagnostics Incorporated's stock symbol?
Quest Diagnostics Incorporated trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."
How often does Quest Diagnostics Incorporated pay dividends? What is the dividend yield for Quest Diagnostics Incorporated?
Quest Diagnostics Incorporated announced a quarterly dividend on Friday, August 18th. Investors of record on Tuesday, October 3rd will be paid a dividend of $0.45 per share on Wednesday, October 18th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.89%. The ex-dividend date of this dividend is Monday, October 2nd. View Quest Diagnostics Incorporated's Dividend History.
How will Quest Diagnostics Incorporated's stock buyback program work?
Quest Diagnostics Incorporated announced that its board has initiated a share repurchase plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 7.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its shares are undervalued.
How were Quest Diagnostics Incorporated's earnings last quarter?
Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings data on Thursday, October, 19th. The company reported $1.39 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analysts' expectations of $1.92 billion. Quest Diagnostics Incorporated had a return on equity of 15.53% and a net margin of 8.82%. The business's quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.37 EPS. View Quest Diagnostics Incorporated's Earnings History.
When will Quest Diagnostics Incorporated make its next earnings announcement?
What guidance has Quest Diagnostics Incorporated issued on next quarter's earnings?
Quest Diagnostics Incorporated issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $5.62-5.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.57. The company issued revenue guidance of $7.69-7.74 billion, compared to the consensus revenue estimate of $7.69 billion.
Where is Quest Diagnostics Incorporated's stock going? Where will Quest Diagnostics Incorporated's stock price be in 2017?
18 brokerages have issued 1 year price objectives for Quest Diagnostics Incorporated's stock. Their forecasts range from $86.00 to $118.00. On average, they anticipate Quest Diagnostics Incorporated's share price to reach $105.14 in the next year. View Analyst Ratings for Quest Diagnostics Incorporated.
What are analysts saying about Quest Diagnostics Incorporated stock?
Here are some recent quotes from research analysts about Quest Diagnostics Incorporated stock:
- 1. According to Zacks Investment Research, "Over the last year, Quest Diagnostics has been trading above the broader industry. The company’s earnings in the last reported quarter exceeded the estimates, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns." (10/3/2017)
- 2. Jefferies Group LLC analysts commented, "We are maintaining our Hold on DGX given our view that significant multiple expansion is unlikely from its current 10-year high P/E. That said, we do not expect its valuation to crack either given the company's stable fundamentals, the emerging opportunity with hospital labs, consistent dividend & buybacks, potential upside from US tax reform, and the composition of its shareholder base." (1/27/2017)
Who are some of Quest Diagnostics Incorporated's key competitors?
Some companies that are related to Quest Diagnostics Incorporated include Laboratory Corporation of America Holdings (LH), DaVita HealthCare Partners (DVA), Universal Health Services (UHS), NMC Health PLC (NMC), HealthSouth Corporation (HLS), Mednax (MD), Acadia Healthcare Company (ACHC), Chemed Corp. (CHE), Select Medical Holdings Corporation (SEM), LifePoint Health (LPNT), Udg Healthcare PLC (UDG), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), China Cord Blood Corporation (CO), HealthStream (HSTM), The Providence Service Corporation (PRSC), Community Health Systems (CYH) and Kindred Healthcare (KND).
Who are Quest Diagnostics Incorporated's key executives?
Quest Diagnostics Incorporated's management team includes the folowing people:
- Stephen H. Rusckowski, Chairman of the Board, President, Chief Executive Officer
- Mark J. Guinan, Chief Financial Officer, Executive Vice President
- James E. Davis, Executive Vice President, General Diagnostics
- Michael E. Prevoznik, Senior Vice President, General Counsel
- Jon Roger Cohen M.D., Senior Vice President, Group Executive - Diagnostic Solutions
- Everett V. Cunningham, Senior Vice President - Commercial
- Catherine T. Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
- Carrie Eglinton Manner, Senior Vice President - Advanced Diagnostics
- Daniel C. Stanzione Ph.D., Lead Independent Director
- Jenne K. Britell Ph.D., Independent Director
Who owns Quest Diagnostics Incorporated stock?
Quest Diagnostics Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional investors include APG Asset Management N.V. (1.97%), Robeco Institutional Asset Management B.V. (0.80%), PGGM Investments (0.26%), State Treasurer State of Michigan (0.23%), Shell Asset Management Co. (0.17%) and Denali Advisors LLC (0.06%). Company insiders that own Quest Diagnostics Incorporated stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, Jeffrey M Leiden, Jenne K Britell, John B Ziegler, Michael E Prevoznik and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics Incorporated.
Who sold Quest Diagnostics Incorporated stock? Who is selling Quest Diagnostics Incorporated stock?
Quest Diagnostics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have sold Quest Diagnostics Incorporated stock in the last year include Catherine T Doherty, Daniel Stanzione, Jeffrey M Leiden, Jenne K Britell, Michael E Prevoznik and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics Incorporated.
Who bought Quest Diagnostics Incorporated stock? Who is buying Quest Diagnostics Incorporated stock?
Quest Diagnostics Incorporated's stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., State Treasurer State of Michigan, Shell Asset Management Co., PGGM Investments, Robeco Institutional Asset Management B.V., Denali Advisors LLC and Foster & Motley Inc.. View Insider Buying and Selling for Quest Diagnostics Incorporated.
How do I buy Quest Diagnostics Incorporated stock?
Shares of Quest Diagnostics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quest Diagnostics Incorporated's stock price today?
MarketBeat Community Rating for Quest Diagnostics Incorporated (NYSE DGX)MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Quest Diagnostics Incorporated stock can currently be purchased for approximately $95.08.
Consensus Ratings for Quest Diagnostics Incorporated (NYSE:DGX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 11 Hold Ratings, 6 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.28)|
|Consensus Price Target: ||$105.14 (10.58% upside)|Consensus Price Target History for Quest Diagnostics Incorporated (NYSE:DGX)
Analysts' Ratings History for Quest Diagnostics Incorporated (NYSE:DGX)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||Wells Fargo & Company||Lower Price Target||Market Perform||$88.00 -> $86.00||N/A|
|10/20/2017||Citigroup Inc.||Lower Price Target||Neutral||$110.00 -> $98.00||N/A|
|10/19/2017||Mizuho||Set Price Target||Buy -> Buy||$122.00 -> $103.00||N/A|
|10/17/2017||Craig Hallum||Reiterated Rating||Hold||$110.00 -> $100.00||N/A|
|10/15/2017||SunTrust Banks, Inc.||Set Price Target||Hold||$105.00||N/A|
|10/10/2017||Goldman Sachs Group, Inc. (The)||Downgrade||Conviction-Buy -> Buy||$121.00 -> $113.00||N/A|
|9/28/2017||Credit Suisse Group||Lower Price Target||Neutral||$110.00 -> $99.00||Low|
|9/25/2017||Raymond James Financial, Inc.||Reiterated Rating||Outperform -> Market Perform||High|
|9/13/2017||Canaccord Genuity||Reiterated Rating||Buy||$118.00||Medium|
|8/10/2017||Morgan Stanley||Boost Price Target||Underweight||$87.00 -> $92.00||Low|
|7/25/2017||Bank of America Corporation||Upgrade||Neutral -> Buy||$111.00 -> $118.00||Medium|
|7/25/2017||Piper Jaffray Companies||Boost Price Target||Neutral||$107.00||High|
|7/19/2017||Barclays PLC||Reiterated Rating||Hold||$110.00||Low|
|6/28/2017||Evercore ISI||Reiterated Rating||In-Line||$104.50||Low|
|5/12/2017||Argus||Initiated Coverage||Hold -> Hold||$102.00||Low|
|4/23/2017||Deutsche Bank AG||Reiterated Rating||Buy||$108.00 -> $115.00||Low|
|4/12/2017||FBR & Co||Boost Price Target||Outperform||$103.00 -> $110.00||Low|
|3/16/2017||Jefferies Group LLC||Reiterated Rating||Hold||$96.00||Medium|
|6/24/2016||Jyske Bank||Downgrade||Neutral -> Sell||N/A|
|5/16/2016||Robert W. Baird||Reiterated Rating||Hold||N/A|
|4/22/2016||Royal Bank Of Canada||Boost Price Target||Sector Perform||$70.00 -> $76.00||N/A|
|1/29/2016||William Blair||Reiterated Rating||Hold||N/A|
Earnings History for Quest Diagnostics Incorporated (NYSE:DGX)Earnings History by Quarter for Quest Diagnostics Incorporated (NYSE DGX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/25/2018|| || || || || || || || |
|10/19/2017||Q3 2017||$1.35||$1.39||$1.92 billion||$1.93 billion||View||N/A|
|7/25/2017||Q2 2017||$1.42||$1.55||$1.94 billion||$1.94 billion||View||N/A|
|4/20/2017||Q1 2017||$1.18||$1.33||$1.87 billion||$1.90 billion||View||N/A|
|1/26/2017||Q416||$1.27||$1.31||$1.86 billion||$1.86 billion||View||Listen|
|10/20/2016||Q316||$1.35||$1.37||$1.53 billion||$1.89 billion||View||Listen|
|7/21/2016||Q216||$1.32||$1.34||$1.91 billion||$1.91 billion||View||Listen|
|4/21/2016||Q116||$1.12||$1.12||$1.82 billion||$1.86 billion||View||Listen|
|1/28/2016||Q415||$1.19||$1.19||$1.85 billion||$1.85 billion||View||Listen|
|10/22/2015||Q315||$1.26||$1.28||$1.89 billion||$1.88 billion||View||Listen|
|7/23/2015||Q215||$1.23||$1.25||$1.93 billion||$1.93 billion||View||Listen|
|4/23/2015||Q115||$1.04||$1.05||$1.85 billion||$1.84 billion||View||Listen|
|1/29/2015||Q414||$1.05||$1.08||$1.85 billion||$1.90 billion||View||Listen|
|10/23/2014||Q314||$1.08||$1.10||$1.87 billion||$1.90 billion||View||Listen|
|7/24/2014||Q214||$1.06||$1.08||$1.88 billion||$1.90 billion||View||N/A|
|4/24/2014||Q114||$0.89||$0.84||$1.75 billion||$1.75 billion||View||Listen|
|1/30/2014||Q413||$0.93||$0.97||$1.74 billion||$1.76 billion||View||Listen|
|10/17/2013||Q313||$1.20||$1.02||$1.84 billion||$1.79 billion||View||Listen|
|7/18/2013||Q2 2013||$1.10||$1.06||$1.84 billion||$1.82 billion||View||Listen|
|4/17/2013||Q1 2013||$1.03||$0.89||$1.86 billion||$1.80 billion||View||Listen|
|1/23/2013||Q4 2012||$1.02||$1.01||$1.83 billion||$1.77 billion||View||Listen|
Earnings Estimates for Quest Diagnostics Incorporated (NYSE:DGX)
2017 EPS Consensus Estimate: $5.36
2018 EPS Consensus Estimate: $5.83
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Quest Diagnostics Incorporated (NYSE:DGX)
|Most Recent Dividend:||10/18/2017|
|Dividend Growth:||9.60% (3 Year Average)|
|Payout Ratio:||37.74% (Trailing 12 Months of Earnings) |
31.97% (Based on This Year's Estimates)
30.87% (Based on Next Year's Estimates)
|Track Record:||5 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Quest Diagnostics Incorporated (NYSE DGX)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Quest Diagnostics Incorporated (NYSE:DGX)
Insider Ownership Percentage: 1.75%Insider Trades by Quarter for Quest Diagnostics Incorporated (NYSE:DGX)
Institutional Ownership Percentage: 86.99%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/12/2017||Stephen H Rusckowski||Chairman||Sell||59,235||$108.16||$6,406,857.60|| |
|9/11/2017||Daniel Stanzione||Director||Sell||40,900||$108.07||$4,420,063.00|| |
|9/11/2017||Stephen H Rusckowski||CEO||Sell||53,933||$108.16||$5,833,393.28|| |
|9/5/2017||Daniel Stanzione||Director||Sell||3,803||$108.01||$410,762.03|| |
|9/5/2017||Stephen H Rusckowski||Chairman||Sell||2,525||$108.03||$272,775.75|| |
|8/4/2017||Jeffrey M Leiden||Director||Sell||296||$106.66||$31,571.36|| |
|7/27/2017||Jeffrey M Leiden||Director||Sell||1,304||$108.73||$141,783.92|| |
|6/19/2017||Catherine T Doherty||SVP||Sell||59,762||$107.55||$6,427,403.10|| |
|4/24/2017||Jenne K Britell||Director||Sell||6,111||$104.03||$635,727.33|| |
|4/20/2017||Michael E Prevoznik||SVP||Sell||29,513||$100.00||$2,951,300.00|| |
|3/16/2017||Michael E Prevoznik||SVP||Sell||13,987||$100.00||$1,398,700.00|| |
|3/3/2017||Catherine T Doherty||SVP||Sell||7,162||$98.28||$703,881.36|| |
|2/27/2017||Michael E Prevoznik||SVP||Sell||440||$97.39||$42,851.60|| |
|1/30/2017||Catherine T Doherty||SVP||Sell||80,000||$90.58||$7,246,400.00|| |
|8/19/2016||Jenne K Britell||Director||Sell||4,000||$84.76||$339,040.00|| |
|8/10/2016||Jenne K Britell||Director||Sell||4,000||$85.20||$340,800.00|| |
|8/3/2016||Jeffrey M Leiden||Director||Sell||6,345||$85.62||$543,258.90|| |
|7/25/2016||John B. Ziegler||Director||Sell||1,000||$84.36||$84,360.00|| |
|5/27/2016||Catherine T Doherty||SVP||Sell||47,334||$77.27||$3,657,498.18|| |
|5/12/2016||Jenne K Britell||Director||Sell||8,000||$75.68||$605,440.00|| |
|5/9/2016||Everett Cunningham||SVP||Sell||56,312||$76.26||$4,294,353.12|| |
|5/6/2016||Everett Cunningham||SVP||Sell||50,447||$76.00||$3,833,972.00|| |
|4/25/2016||Catherine T Doherty||SVP||Sell||29,550||$74.45||$2,199,997.50|| |
|3/3/2015||Michael E Prevoznik||SVP||Sell||3,261||$71.16||$232,052.76|| |
|2/11/2015||Daniel Stanzione||Director||Sell||8,000||$70.97||$567,760.00|| |
|2/4/2015||Gail R Wilensky||Director||Sell||8,000||$72.34||$578,720.00|| |
|2/3/2015||John B Ziegler||Director||Sell||8,000||$71.88||$575,040.00|| |
|2/2/2015||Thomas F Bongiorno||VP||Sell||3,000||$71.50||$214,500.00|| |
|11/17/2014||Jon R Cohen||SVP||Sell||160,029||$63.13||$10,102,630.77|| |
|8/8/2014||Catherine T Doherty||SVP||Sell||25,000||$60.12||$1,503,000.00|| |
|8/4/2014||Michael E Prevoznik||SVP||Sell||14,377||$61.01||$877,140.77|| |
|7/30/2014||Jenne K Britell||Director||Sell||8,000||$62.37||$498,960.00|| |
|7/30/2014||Michael E Prevoznik||SVP||Sell||16,384||$62.51||$1,024,163.84|| |
|7/29/2014||John C Md Baldwin||Director||Sell||8,000||$62.31||$498,480.00|| |
|7/28/2014||Thomas F Bongiorno||VP||Sell||4,000||$61.72||$246,880.00|| |
|7/25/2014||John B Ziegler||Director||Sell||8,000||$61.90||$495,200.00|| |
|5/22/2014||John Ziegler||Director||Sell||2,973||$57.65||$171,393.45|| |
|5/7/2014||Gary Pfeiffer||Director||Sell||10,000||$55.95||$559,500.00|| |
|5/5/2014||Mark Guinan||CFO||Buy||4,000||$55.51||$222,040.00|| |
|2/27/2014||Jenne Britell||Director||Sell||10,000||$52.74||$527,400.00|| |
|2/19/2014||Michael Prevoznik||SVP||Sell||2,860||$52.26||$149,463.60|| |
|2/18/2014||Gail Wilensky||Director||Sell||30,000||$52.93||$1,587,900.00|| |
|2/6/2014||Timothy Main||Director||Buy||5,000||$50.71||$253,550.00|| |
|11/5/2013||Thomas F Bongiorno||VP||Sell||16,667||$62.49||$1,041,520.83|| |
|10/29/2013||Thomas F Bongiorno||VP||Sell||6,000||$59.00||$354,000.00|| |
|10/25/2013||Gary M Pfeiffer||Director||Sell||2,000||$58.10||$116,200.00|| |
|9/17/2013||Catherine Doherty||SVP||Sell||43,334||$62.00||$2,686,708.00|| |
|8/14/2013||Catherine Doherty||SVP||Sell||33,000||$59.85||$1,975,050.00|| |
|8/12/2013||John Ziegler||Director||Sell||1,953||$59.45||$116,105.85|| |
|8/8/2013||Thomas Bongiorno||VP||Sell||10,864||$59.33||$644,561.12|| |
|7/23/2013||Jenne K Britell||Director||Sell||4,200||$58.99||$247,758.00|| |
|6/18/2013||Michael E Prevoznik||SVP||Sell||126,667||$62.64||$7,934,420.88|| |
|5/22/2013||John B Ziegler||Director||Sell||31,362||$62.00||$1,944,444.00|| |
|5/14/2013||John C Md Baldwin||Director||Sell||1,214||$59.41||$72,123.74|| |
|4/11/2013||John B Ziegler||Director||Sell||1,470||$58.35||$85,774.50|| |
|1/17/2013||Gary M Pfeiffer||Director||Sell||10,000||$60.00||$600,000.00|| |
|10/3/2012||Robert Hagemann||CFO||Sell||46,667||$64.00||$2,986,688.00|| |
|8/7/2012||Stephen H Rusckowski||CEO||Buy||5,000||$59.34||$296,700.00|| |
Headline Trends for Quest Diagnostics Incorporated (NYSE:DGX)
Latest Headlines for Quest Diagnostics Incorporated (NYSE:DGX)
Loading headlines, please wait.
Quest Diagnostics Incorporated (DGX) Chart for Sunday, October, 22, 2017